MedTrace Logo

Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer

NCT01006785 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2012-10-18

No results posted yet for this study

Summary

The purposes of this study are :

* to investigate the safety and clinical efficacy of sole therapy with DLBS1425 in suppressing disease-(tumour) progression in subjects with advanced/metastatic breast cancer; and
* to determine the minimal effective and safe dose of DLBS1425 in the therapy of advanced/metastatic breast cancer

Conditions

Interventions

DRUG

DLBS1425

3 X 150 mg daily for 12 - 16 weeks of treatment

DRUG

DLBS1425

3 X 300 mg daily for 12 - 16 weeks of treatment

Sponsors & Collaborators

  • Dexa Medica Group

    lead INDUSTRY

Principal Investigators

  • Abdul Muthalib, Prof. Dr. · Division of Medical Haematology and Oncology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia / Dr. Cipto Mangunkusumo Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01006785 on ClinicalTrials.gov